Neurogenic Orthostatic Hypotension
16
5
5
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
6.3%
1 terminated out of 16 trials
87.5%
+1.0% vs benchmark
31%
5 trials in Phase 3/4
71%
5 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (16)
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
Hypercapnia in Orthostatic Hypotension
CO2 Rebreathing in nOH: A Proof-of-Concept Pilot Study
A Study in Subjects With Neurogenic Orthostatic Hypotension
CPAP for the Treatment of Supine Hypertension
Natural History Study of Synucleinopathies
Controlled CO2 Inhalation in NOH
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension
Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Brain Perfusion & Oxygenation in Parkinson's Disease With NOH
Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH
Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)